<DOC>
	<DOCNO>NCT02314117</DOCNO>
	<brief_summary>The main purpose study evaluate effectiveness ramucirumab , target antibody , combination capecitabine cisplatin compare capecitabine cisplatin alone participants stomach cancer .</brief_summary>
	<brief_title>A Study Ramucirumab ( LY3009806 ) Combination With Capecitabine Cisplatin Participants With Stomach Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Have histopathologically confirm diagnosis metastatic gastric gastroesophageal junction ( GEJ ) adenocarcinoma . All histology nonsquamous cell origin include undifferentiated gastric carcinoma eligible . Have receive prior firstline systemic therapy ( prior adjuvant neoadjuvant therapy permit ) . Participants whose disease progress &gt; 12 month follow last dose systemic treatment adjuvant/neoadjuvant set eligible . Have measurable nonmeasurable evaluable disease determine use guideline Response Evaluation Criteria Solid Tumors , Version 1.1 ( RECIST v 1.1 ) . Baseline tumor assessment perform use high resolution compute tomography ( CT ) scan use IV oral contrast unless clinically contraindicate . Magnetic resonance imaging ( MRI ) acceptable CT performed . Have performance status 0 1 Eastern Cooperative Oncology Group scale baseline . Have adequate organ function . Have baseline clinical laboratory parameter consistent requirement prescribe respective label suitable consideration treatment capecitabine ( 5FU ) cisplatin ( example , dihydropyrimidine dehydrogenase deficiency ) . Have estimate life expectancy ≥12 week judgment investigator . Participants adenocarcinoma esophagus exclude . Participants human epidermal growth factor receptor 2 ( HER2 ) positive status . Participants receive chronic therapy nonsteroidal antiinflammatory agent . Have radiation therapy within 14 day prior randomization . Have document brain metastasis , leptomeningeal disease uncontrolled spinal cord compression . Have significant bleeding disorder , vasculitis , significant bleeding episode gastrointestinal tract within 12 week prior randomization . Have experience arterial thromboembolic event , include myocardial infarction , unstable angina , cerebrovascular accident , transient ischemic attack , within 6 month prior randomization . Have symptomatic congestive heart failure ( New York Heart Association IIIV ) symptomatic poorly control cardiac arrhythmia . Have uncontrolled hypertension prior initiate study treatment , despite antihypertensive intervention . Have undergone major surgery within 28 day prior randomization , central venous access device placement within 7 day prior first dose study treatment , except procedure minimally invasive ( example , introduction peripherally inserted central catheter [ PICC ] line ) investigator anticipate significant bleeding . Have history gastrointestinal perforation and/or fistula within 6 month prior randomization . Have history inflammatory bowel disease Crohn 's disease require medical intervention ( immunomodulatory immunosuppressive medication surgery ) ≤12 month prior randomization . Have acute subacute bowel obstruction history chronic diarrhea consider clinically significant opinion investigator . The participant : cirrhosis level ChildPugh B ( bad ) cirrhosis ( degree ) history hepatic encephalopathy clinically meaningful ascites result cirrhosis . Clinically meaningful ascites define ascites result cirrhosis require ongoing treatment diuretic and/or paracentesis . Have know allergy hypersensitivity component study treatment . Are pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>